In short
This article discusses the clinical trials of SCO-101, a drug containing N-[4-Bromo-2-(1H-1,2,3,4-Tetrazol-5-Yl)Phenyl]-N'-[3,5- Bis(Trifluoromethyl)Phenyl]Urea, in combination with FOLFIRI for treating metastatic colorectal cancer (mCRC). The trials aim to evaluate the safety, tolerability, and effectiveness of this combination therapy in patients who have developed resistance to standard FOLFIRI treatment.
At a glance
- Study Type
- Phase II open-label clinical trial
- Drug Studied
- SCO-101 (N-[4-Bromo-2-(1H-1,2,3,4-Tetrazol-5-Yl)Phenyl]-N'-[3,5- Bis(Trifluoromethyl)Phenyl]Urea) in combination with FOLFIRI
- Target Condition
- Metastatic Colorectal Cancer (mCRC) resistant to FOLFIRI
- Main Objectives
- Determine safety, toxicity profile, maximum tolerated dose, and objective response rate
- Key Eligibility Criteria
- Adults with mCRC, previous FOLFIRI treatment, disease progression on standard treatments
- Primary Endpoints
- Safety, tolerability, maximum tolerated dose, objective response rate
- Secondary Endpoints
- Progression-free survival, duration of response, overall survival, pharmacokinetics, biomarker evaluation
Introduction to SCO-101
SCO-101, also known as N-[4-BROMO-2-(1H-1,2,3,4-TETRAZOL-5-YL)PHENYL]-N'-[3,5- BIS(TRIFLUOROMETHYL)PHENYL]UREA, is a promising new drug being developed for the treatment of metastatic colorectal cancer (mCRC). This medication is currently being studied in patients whose cancer has become resistant to standard treatments.
How SCO-101 Works
SCO-101 is classified as a chloride channel inhibitor. While the exact mechanism is not fully explained in the provided information, chloride channel inhibitors generally work by blocking certain channels in cancer cells, which can interfere with their growth and survival. This unique approach may help overcome resistance to other treatments.
Current Clinical Trial
A phase II clinical trial is currently underway to investigate SCO-101 in combination with a chemotherapy regimen called FOLFIRI. This trial aims to determine:
- The safety and side effects of SCO-101 when used with FOLFIRI
- The most effective and safe dose of SCO-101
- How well the combination works in treating metastatic colorectal cancer
The trial is divided into three stages, each focusing on different aspects of the treatment and different patient groups.
Who Can Participate in the Trial?
The trial is designed for patients with metastatic colorectal cancer who have specific characteristics. Some key eligibility criteria include:
- Age 18 years or older
- Confirmed diagnosis of metastatic colorectal cancer
- Previous treatment with certain chemotherapy drugs (irinotecan and 5-FU) that is no longer working
- Good overall health status
It's important to note that there are many other specific criteria that doctors use to determine if a patient is eligible for the trial. These criteria help ensure the safety of participants and the reliability of the study results.
Safety and Side Effects
As with any new treatment, understanding the safety profile of SCO-101 is a crucial part of the clinical trial. The researchers will be closely monitoring participants for any side effects or adverse reactions. Some potential areas of concern that will be watched include:
- Changes in blood cell counts
- Liver function
- Kidney function
- Cardiovascular health
It's important to remember that all medical treatments can have side effects, and the purpose of this trial is to better understand both the benefits and risks of SCO-101.
Potential Benefits of SCO-101
While it's too early to know for certain, the researchers hope that SCO-101, when combined with FOLFIRI chemotherapy, may offer several potential benefits for patients with metastatic colorectal cancer:
- Improved response to treatment: The trial will measure how many patients experience tumor shrinkage (called "objective response rate")
- Longer-lasting benefits: Researchers will look at how long the treatment keeps working before the cancer starts growing again
- Extended survival: The study will track how long patients live after starting the treatment
- Overcoming drug resistance: SCO-101 may help make chemotherapy effective again in patients whose cancer has become resistant to standard treatments
It's important to note that these are potential benefits that the trial aims to investigate. The actual effectiveness of SCO-101 will only be known after the trial is completed and the results are analyzed.